Biotech News

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana plc (NCNA)NuCana plc2026-03-19 20:01 ESTEarnings

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United

Related news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

View all latest news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-06-01 12:00 EST

NuCana Appoints Ian Webster as Chief Financial Officer

NCNANuCana plc2026-05-14 20:01 EST

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-03-19 20:01 EST

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NCNANuCana plc2026-01-06 13:00 EST

NuCana Appoints Theresa Bruce as Chief Operating Officer

Stock data

Close: 1.52 USD
Market cap: 8.62M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States